FIELD: chemistry.
SUBSTANCE: invention relates to a substituted polypeptide of formula I'-B, where AA1-AA5, WC, RC are defined in the claims, or a pharmaceutically acceptable salt thereof, which has the inhibitory effect of MMP2. Also disclosed is a pharmaceutical preparation, an MMP2 inhibitor and a drug having MMP2 inhibitory activity.
EFFECT: disclosed is a polypeptide having mmr-2 inhibitory action.
5 cl, 53 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2744959C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2776121C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| SWINE G-CSF VARIANTS AND APPLICATION THEREOF | 2018 |
|
RU2823074C2 |
| KV1_3 BLOCKERS | 2020 |
|
RU2825633C1 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
